The results add to evidence for the potential of ctDNA tumor fraction as a new monitoring tool that could allow clinical researchers to detect tumor progression and change treatment strategies earlier than through current methods.

DNA methylation analysis in the blood, powered by advances in wet-lab chemistry and bioinformatics, has enabled the use of epigenomic profiling to enhance the sensitivity of liquid biopsy, providing a deeper understanding of tumor biology and expanding the promise of precision oncology beyond what genomic information can offer.

For the benefits of precision medicine to be fully realized, more laboratories must be able to access NGS technologies in-house, and NGS results must be delivered to patients faster.

Illumina’s new software platform, designed to reduce tertiary analysis time and ease reporting, launches in multiple global markets as experts say the volume of clinical NGS data is ballooning. 

In the wake of a transformational period for bladder cancer treatment, the time is right to harness integrated care coordination and precision medicine in order to optimize patient outcomes across the disease continuum. 

The noninvasive test evaluates eight 3D genomic markers and is the only test that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to an ICI.

The translation of bench research into the clinical environment has accelerated significantly in recent years, highlighting the challenges of translating new techniques into regulated, scalable methodologies and increasing the need for clinically validated workflows.

Precision oncology will only be a reality for all patients if there is collaboration between the different stakeholders within the healthcare system — such as industry partners, academia, and regulatory bodies — to increase patient access.

Advances in proteomics are improving cancer biomarker discovery, drug discovery, and drug target validation.